Intra‐abdominal infectious complications within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: anti‐integrin agents changes intra‐abdominal infectious complications within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Extra‐abdominal infections within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: anti‐integrin agents changes extra‐abdominal infections within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Incisional infections and wound dehiscence within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes incisional infections and wound dehiscence within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Intra‐abdominal infectious complications within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes intra‐abdominal infectious complications within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Extra‐abdominal infections within 30 days of surgery · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: corticosteroids changes extra‐abdominal infections within 30 days of surgery compared with control (very low certainty).
1 finding from 1 review
Infectious complications · people with inflammatory bowel disease
It is very uncertain whether risk of postoperative infectious complications: 5‐ASA changes overall infectious complications within 30 days of surgery compared with control (very low certainty).
3 findings from 1 review
OR 0.76 [0.51, 1.14]
6 studies · 6 participants
Very low
no estimate extracted
0 studies · 0 participants
GRADE not reported
OR 0.76 [0.51, 1.14]
6 studies · 6 participants
Very low
Complete miscarriage · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher complete miscarriage compared with placebo (low certainty).
1 finding from 1 review
Nausea · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher nausea compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Diarrhoea · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher diarrhoea compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Blood loss: post‐treatment haematocrit (%) · early fetal death (less than 24 weeks)
1 finding from 1 review
Patient‐reported pain intensity or pain relief (VAS, NRS or categorical scale) · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to higher pain relief compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Woman’s satisfaction/acceptability of method · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Pelvic infection · early fetal death (less than 24 weeks)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nausea · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in nausea compared with placebo (low certainty).
1 finding from 1 review
Diarrhoea · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in diarrhoea compared with placebo (low certainty).
1 finding from 1 review
Blood loss: haemoglobin difference > 10 g/L · early fetal death (less than 24 weeks)
It is very uncertain whether vaginal misoprostol changes blood loss: haemoglobin difference > 10 g/L compared with placebo (very low certainty).
1 finding from 1 review
Opiate use (as a proxy measure for pain) for all participants on ITT (including those without confirmed AMI) · early fetal death (less than 24 weeks)
It is very uncertain whether vaginal misoprostol changes pain (opiate use) compared with placebo (very low certainty).
1 finding from 1 review
Woman’s satisfaction/acceptability of method · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in woman’s satisfaction/acceptability of method compared with placebo (low certainty).
1 finding from 1 review
Complete miscarriage · early fetal death (less than 24 weeks)
Vaginal misoprostol may leads to lower complete miscarriage compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review
Pelvic infection · early fetal death (less than 24 weeks)
Vaginal misoprostol showed no clear difference in pelvic infection compared with surgical evacuation of uterus (low certainty).
1 finding from 1 review